New Slow-Release pill for muscle disease tested in healthy volunteers

NCT ID NCT07154095

Completed Knowledge-focused Sponsor: West China Second University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new sustained-release (long-acting) version of pyridostigmine, a drug used for myasthenia gravis (a muscle weakness disease). Forty healthy Chinese adults took both the new long-acting tablet and the standard immediate-release tablet at different times to compare how the drug moves through the body and to check for side effects. The goal is to see if the new version can provide steady drug levels with fewer daily doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pyridostigmine
What this could lead to: If successful, this sustained-release tablet could allow people with myasthenia gravis to take medication less often while maintaining stable drug levels.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. The new tablet may not work better or could cause unexpected side effects when tested in people with the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS PHARMACOKINETICS

Contacts and locations

Locations

West China Second University Hospital

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.